Recursion Pharmaceuticals Stock News

Recursion Pharmaceuticals (RXRX 1.84%), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at all) as it does now on Wall Street. Although things have changed on that front, Recursion has not benefited from the skyrocketing interest in AI companies.

The artificial intelligence (AI) revolution has the potential to alter just about every business operation for the better. One area where investors are extra excited about productivity improvements is the drug development business.

While Nvidia and Microsoft dominate artificial intelligence (AI) headlines, the smartest opportunities might lurk in smaller companies solving specific problems with the tech. These 10 hidden gems don't build foundation models or design AI chips -- they apply existing AI technology to transform inefficient industries and outdated processes.

BigBear.ai (BBAI -6.00%) has taken investors on a rollercoaster ride in 2025. The good news, though, is that they're probably enjoying the ride these days.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Rese...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Ben Taylor - CFO & President of Recursion UK Conference Call Participants Andrew Pucher Presentation Andrew Pucher Welcome to this afternoon session with Recursion. My name is Andrew Pucher.

The real artificial intelligence (AI) opportunity isn't hiding in the obvious names that dominate headlines. It's emerging in industries that have barely changed in decades -- and are now primed for AI-driven disruption.

Prosper Junior Bakiny has positions in Nvidia and Recursion Pharmaceuticals. The Motley Fool has positions in and recommends Nvidia.